Re: Semaglutide reduces risk of major cardiovascular events by 20%, finds study

Agreement: 
I Agree
Body: 

Dear Editor

Further to the response by David Phizackerley I can only wonder at the lack of absolute risk [AR] reduction figures and numbers needed to treat [NNT] in this paper. Have we learned nothing? What happened to evidence based medicine and peer review?

No competing Interests: 
Yes
The following competing Interests: 
Electronic Publication Date: 
Saturday, November 18, 2023 – 11:38
Workflow State: 
Released
Full Title: 

Re: Semaglutide reduces risk of major cardiovascular events by 20%, finds study

Check this box if you would like your letter to appear anonymously:: 
Last Name: 
Price
First name and middle initial: 
Simon
Address: 
4 Oakdene Gardens
Occupation: 
retired GP
Affiliation: 
nil
BMJ: Additional Article Info: 
Rapid response

Leave a Reply

error: Content is protected !!
Open chat
WhatsApp Now